17,261 trials
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Response — 12; 6; 5 participants
Autism Spectrum Disorder
Primary: Change From Baseline in the Pervasive Developmental Disorder-Behavioral Inventory (PDDBI) - Autism Composite Score — -4.5; -6.4 units on a scale — p=0.5
Primary Total Knee Arthroplasty
Primary: Postoperative Pain — 4; 4.8; 4.5; 4.0 units on a scale
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Primary: Therapy Completion Rate — .75 proportion of participants
Breast Neoplasms
Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline
Plasma Cell Disorder
Primary: Positive for Hepatitis B Surface Antigen — 4; 3 participants
GIST
Primary: Clinical Benefit Rate (CBR) in Cohort A — 35.7 percentage (%) of participants
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Primary: Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration. — 3.6; 5.3; 7.9 mmol/L
Pulmonary Arterial Hypertension
Primary: Number of Participants That Were Succesfully Transitioned From Parenteral Remodulin to UT-15C. — 31 participants
Plaque Psoriasis
Primary: Adrenal Suppression Potential — 16; 18; 5; 3 participants
Hypoglycemia
Primary: Serious Adverse Events — 0; 0; 0 participants
Crohn's Disease
Primary: Mean Serum Adalimumab Concentration at Week 8 — 7.99; 10.0 μg/mL
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Progression Free Survival — 3.75; 3.68 months
Her2 Negative Breast Cancer Patients
Primary: Progression Free Survival (PFS) — 15.9; 10.7 weeks
Leukemia · Lymphoma
Primary: Overall Response — 11; 23; 4; 5 participants